Ormat Technologies insider plans modest $130K share sale (Form 144)
Rhea-AI Filing Summary
Form 144 Overview: An unidentified affiliate of Ormat Technologies, Inc. (ORA) has filed a Form 144 indicating an intention to sell 1,500 shares of the company’s common stock. The filing is a notice rather than a confirmation of sale and pertains to Rule 144 under the Securities Act of 1933.
Key Details
- Shares to be sold: 1,500 common shares
- Estimated market value: US $129,600.75
- Broker: Morgan Stanley Smith Barney LLC, Executive Financial Services, New York
- Planned sale date: on or about 24 June 2025
- Exchange: NYSE
- Total shares outstanding: 60,662,626; proposed sale equals roughly 0.0025 % of the float—an immaterial level.
Acquisition History of the Shares
- 358 restricted shares acquired 01 Mar 2023
- 90 restricted shares acquired 31 Dec 2023
- 1,052 restricted shares acquired 31 Dec 2022
No sales were reported by the filer in the past three months, and the form states that the filer is not in possession of any undisclosed material adverse information about the company. Because the proposed transaction represents a very small fraction of outstanding shares, market impact is expected to be negligible. Nevertheless, investors often monitor Form 144 filings as signals of insider sentiment and potential liquidity events.
Positive
- None.
Negative
- Insider intends to sell 1,500 shares (~0.0025% of outstanding), which may be interpreted as a mild negative signal of insider sentiment despite its immaterial size.
Insights
TL;DR: Insider plans to sell 1,500 ORA shares (~0.0025% float); signaling minimal impact, but insider sentiment worth noting.
The Form 144 indicates an affiliate’s intent to dispose of a modest block of Ormat Technologies stock. Quantitatively, 1,500 shares valued at roughly $130k are immaterial against a 60.7 million-share base, suggesting virtually no dilution or price pressure. Qualitatively, any insider sale can raise questions on confidence levels, yet the restricted-stock origin ties the shares to normal vesting rather than discretionary open-market accumulation, tempering concerns. No prior three-month sales and the required affirmation of no undisclosed adverse information further reduce red flags. Overall, the filing is routine, with neutral governance implications for investors.